DALAM 2 KISAH
BY : LYLA
intro : C G Em D
C G
kau takkan terganti
Am Em
meski menjadi lembaran buram
D C
di buku hidupku
G
harusnya berhenti
Am Em
melukis hati di dalam kelam
D
kanvas pikiranmu
C Am Em D
salah ku bersalah
C Am Em D C
marah dalam dua kisah
Chorus :
G C
maafkanlah tuk segala luka
D G
yang mendera meleburkan jiwa
Em Am
sungguh rasaku benar adanya
C D G
tapi tak bisa ku melepaskan dia
C G
aku harusnya berhenti
Am Em D
sedari dulu bermain dengan melukis hatimu
C Am Em D
salah ku bersalah
C Am Em D C
marah dalam dua kisah oooo oooo
Chorus :
G C
maafkanlah tuk segala luka
D G
yang mendera meleburkan jiwa
Em Am
sungguh rasaku benar adanya
C D G
tapi tak bisa ku melepaskan dia
G C
pahamilah pepatah pujangga
D G
kadang cinta tak mesti bersama
Em Am
biar seperti ini adanya
C D
simpanlah sebagai kenangan yang tersisa
Solo : C D Em D
C D
Chorus :
G C
maafkanlah tuk segala luka
D G
yang mendera meleburkan jiwa
Em Am
sungguh rasaku benar adanya
C D G
tapi tak bisa ku melepaskan dia
G C
pahamilah pepatah pujangga
D G
kadang cinta tak mesti bersama
Em Am
biar seperti ini adanya
C D
simpanlah sebagai kenangan yang tersisa
Outro : C G Em D
It's the Catch-22 of clinical trials: to protect pregnant women and children from the risks of untested drugs....we don't test drugs adequately for them. In the last few decades , we've been more concerned about the harms of research than of inadequately tested treatments for everyone, in fact. But for "vulnerable populations," like pregnant women and children, the default was to exclude them. And just in case any women might be, or might become, pregnant, it was often easier just to exclude us all from trials. It got so bad, that by the late 1990s, the FDA realized regulations and more for pregnant women - and women generally - had to change. The NIH (National Institutes of Health) took action too. And so few drugs had enough safety and efficacy information for children that, even in official circles, children were being called "therapeutic orphans." Action began on that, too. There is still a long way to go. But this month there was a sign that ...
Comments
Post a Comment